427US13BR02006-08-01 Jun/14

ORENCIA® (abatacept) Clinical Results

ORENCIA® (abatacept) has been shown to reduce signs and symptoms in moderate to severe rheumatoid arthritis in both patients who had not responded well enough to methotrexate (MTX) or had not responded well enough to a TNF blocker.

Patients taking ORENCIA were studied in several clinical trials.
Click on the tabs to see details about three of them.

SELECTED IMPORTANT SAFETY INFORMATION
ORENCIA can cause serious side effects including:

 

Hepatitis B infection: If you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can become active while you use ORENCIA. Your healthcare provider may do a blood test before you start or while using ORENCIA.

Study Overviews

  • Trial 1: This study tested ORENCIA intravenous (IV) on 638 adults with moderate to severe rheumatoid arthritis who had not responded well enough to MTX. The participants were given either ORENCIA IV + MTX or MTX alone. At 6 months, the patients' signs and symptoms were measured, and at 1 year, their physical function and joint damage were assessed.
  • Trial 2: This study tested ORENCIA IV on 389 adults with moderate to severe rheumatoid arthritis who had not responded well enough to a TNF* blocker (e.g., Humira® (adalimumab), Enbrel® (etanercept), or Remicade® (infliximab)). The participants were given either ORENCIA IV plus a non-biologic DMARD or a non-biologic DMARD alone. Their signs and symptoms and their physical function were measured at 6 months.
  • Trial 3: This study compared ORENCIA self-injection and ORENCIA IV in 1,457 patients with moderate to severe rheumatoid arthritis who had not responded well enough to MTX. The participants were given ORENCIA self-injection + MTX or ORENCIA IV + MTX. At 6 months, patients' signs and symptoms and their physical function were measured.
*TNF: tumor necrosis factor.
DMARD: disease-modifying antirheumatic drug.

NEXT: Starting on ORENCIA

Font Size: Increase Font Size Decrease Font Size Print This PagePrint Page

ORENCIA® Care Counselors cannot provide medical advice. Your Health Care Provider is the best source of medical information.

All conversations are recorded for quality purposes. Powered by LivePerson™.

Learn more ORENCIA Intravenous (IV) Infusion and Juvenile Idiopathic Arthritis (JIA)

For children 6 years and older with moderate to severe polyarticular JIA.

Support Materials

  • RA Symptom Tracker

    This tool helps your doctor understand how rheumatoid arthritis is affecting you over time. Fill it out over the next few weeks and bring it with you to your next doctor's appointment.

  • Quick RA Checklist

    This tool gives your doctor a quick snapshot of your rheumatoid arthritis symptoms. Complete it right before your next appointment and bring it with you.

  • Personalized Information Kit

    Sign up to receive information designed around your personal rheumatoid arthritis challenges.

Comprehensive Support.
Human Connection.

Questions about Copay?

Call 1-800-ORENCIA to talk
to a live ORENCIA
Care Counselor
located here in the
United States.

Sign up for
our Support
Program:

JOIN ORENCIA On Call JOIN ORENCIA On Call JOIN ORENCIA On Call JOIN ORENCIA On Call JOIN ORENCIA On Call

Want more information on ORENCIA?

Sign up to receive a free Personalized Information Kit.

Sign up now Sign up now

Learn how ORENCIA is taken

Read More

Have questions?
Call 1-800-ORENCIA

About You

About You

There were problems with your form. Please review your entries below.

I am a:
Name:
Address:

We'll send you a free, personalized information kit to this address.
Phone:
- -
E-mail:
Your Date of Birth:

You must be 18 years of age or older to register.
Gender:
Do you prefer to receive information in Spanish, where available?

We take your privacy seriously. For more, read our Privacy Policy.

Continue
Play

At time of filming, this patient was taking ORENCIA® (abatacept) for IV infusion. With the availability of ORENCIA for self- injection, this patient may have chosen, together with her rheumatologist, to take this formulation.

Play

At time of filming, this patient was taking ORENCIA® (abatacept) for IV infusion. With the availability of ORENCIA for self- injection, this patient may have chosen, together with his rheumatologist, to take this formulation.

Play

At time of filming, this patient was taking ORENCIA® (abatacept) for IV infusion. With the availability of ORENCIA for self- injection, this patient may have chosen, together with his rheumatologist, to take this formulation.

Play

At time of filming, this patient was taking ORENCIA® (abatacept) for IV infusion. With the availability of ORENCIA for self- injection, this patient may have chosen, together with her rheumatologist, to take this formulation.